Blood product exports and vaccine sales power the strongest operating performance in years, but a ₩14 billion adverse tax swing and the deconsolidation of GC Wellbeing cut controlling shareholders' net income nearly a third.
Source: Q1 2026 Quarterly Report (58th Fiscal Year, January–March 2026) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
GC Corp posted its strongest quarterly operating result in recent memory in Q1 2026, with revenue climbing 13.5% year-on-year to ₩435.5 billion and operating profit surging 47.3% to ₩11.7 billion — a degree of operating leverage of roughly 3.5x signalling the company has crossed the threshold where its fixed cost base is genuinely being absorbed by incremental volume. Yet the headline net income figures tell a more complicated story: controlling shareholders' net income fell 31.0%, from ₩29.7 billion to ₩20.5 billion, and EPS retreated from ₩2,602 to ₩1,794. The divergence is not a sign of deteriorating operations. Pre-tax income actually expanded 71%, from ₩16.7 billion to ₩28.6 billion. The damage appeared further down the income statement — last year's ₩5.6 billion deferred tax benefit flipped to an ₩8.5 billion expense this quarter, generating a roughly ₩14.0 billion adverse swing in a single line. Layered on top was the disappearance of a base-period effect in which GC Wellbeing's subsidiary losses had been largely absorbed by minority shareholders in Q1 2025, artificially inflating the controlling shareholders' share that quarter. The clean read of Q1 2026 is the operating profit line — and it is up 47%.
